Montai Health CEO Margo Georgiadis is using what she’s learned at McKinsey, Discover, Google, Mattel, and Ancestry to reinvent drug discovery and development, with a focus on long-term safety.

Through the boom and bust of anti-aging buzz cycles, Life Biosciences has continued its focus on epigenetic reprogramming with an increasingly focused pipeline and development strategy.

A rising star in BMS’s finance department, Tatiana Simonelli, SVP, finance commercialization at BMS discusses her path to senior leadership, and how talent diversity can boost business results.

As buzzy development areas buckle down to face the realities of strict regulations, financial demands, and specific unmet needs, the language leaders use to describe their efforts can help, or hurt.

Ashvattha Therapeutics CEO Jeff Cleland hopes to bring hydroxyl dendrimer therapeutics to market for the first time, while also pushing for policy and regulatory change as an advocate for BIO.

Novo Nordisk’s return to growth is largely due to an explosion of demand for its anti-obesity products. However, challenges with supply and insurance coverage persist.

New and improved ways of measuring disease symptoms and responses to therapy must overcome established forms of measurement used for regulatory approval. 

Ahmed Hamdy and Raquel Izumi are putting the lessons, hard knocks, and experiential wisdom they have gained over a decade in biotech to work at Vincerx.

I-MAK, a nonprofit focused on reforming the drug patent system, is bringing patients into the patent system to advocate against abuses that keep affordable drugs out of reach.